3648 results for «2366»
3648 results
New platforms for coronary lesions treatment
21 May 2026 – From EuroPCR 2026
Delve into the latest developments in coronary lesion treatment platforms through this session, highlighting real-world performance data of novel drug-eluting stents like Eternia and Evermine 50. It also presents preclinical insights on biomimetic CD31-coated stents, long-term outcomes of the Fantom BRS platform, and innovative randomized trials...
Mitral interventions: procedural risk assessment and interventions
21 May 2026 – From EuroPCR 2026
Focused on mitral valve interventions, this session covers procedural risk assessment and outcomes following transcatheter edge-to-edge repair (TEER). Topics include predictive risk scores, technical complexity, pulmonary artery pressure indices, right ventricle-pulmonary artery coupling, and novel imaging predictors influencing procedural success and patient prognosis.
Risk stratification and reperfusion strategies for acute and subacute pulmonary embolism
21 May 2026 – From EuroPCR 2026
Focus on risk stratification and reperfusion strategies for acute and subacute pulmonary embolism through this session. It discusses the impact of elective endovascular therapies in intermediate-high risk patients, intraprocedural complications, and early mortality associated with catheter interventions. Additionally, it reviews real-world outcomes of catheter-directed therapy, national...
Ambiguous left main lesions: how to assess severity and make the right decision
21 May 2026 – From EuroPCR 2026
Addressing the complexities of ambiguous left main coronary lesions, this session elucidates the integration of physiology, intracoronary imaging, and CT scanning for comprehensive assessment. It highlights multimodality diagnostic strategies and decision-making frameworks to guide appropriate revascularization.
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
Percutaneous management of mitral and aortic valve disease
21 May 2026 – From EuroPCR 2026
Delve into the percutaneous management of mitral and aortic valve disease through detailed procedural demonstrations. This session covers valve-in-valve procedures, navigation of potential complications in valve-in-valve TAVI, and mitral valve edge-to-edge repair techniques, supported by real-world case discussions and key learnings.
Complex multivessel disease: from calcium to physiology - Case-based decisions
21 May 2026 – From EuroPCR 2026
Focus on complex multivessel coronary artery disease management with an emphasis on severely calcified lesions and the integration of intracoronary imaging and physiology. This session prepares clinicians to anticipate and manage complications during PCI, enhancing competence in treating challenging coronary anatomies through case-based decision-making.
Overcoming complications with intracoronary imaging
21 May 2026 – From EuroPCR 2026
Explore challenging cases of intracoronary imaging complications, highlighting recognition, management, and resolution of complex vascular and mechanical issues encountered during coronary interventions.
Beyond stent: use of DCB in CTO
22 May 2026 – From EuroPCR 2026
This session focuses on the innovative use of drug-coated balloons (DCB) in chronic total occlusion (CTO) interventions. It reviews combined plaque modification techniques, complex multivessel PCI cases involving CTOs, and strategy considerations such as hybrid therapy versus full metal jacket, emphasizing vessel biology preservation during revascularisation.
Refining management of NSTEMI
21 May 2026 – From EuroPCR 2026
This session refines NSTEMI management by exploring advanced diagnostic tools, risk stratification, and tailored revascularization strategies, including bleeding risk assessment and dual antiplatelet therapy considerations.
Hybrid percutaneous revascularisation: combining DES and DCB for optimal results
21 May 2026 – From EuroPCR 2026
This session delves into hybrid percutaneous revascularisation techniques that combine drug-eluting stents (DES) and drug-coated balloons (DCB) to achieve optimal clinical results. It highlights the clinical and anatomical scenarios suited for hybrid PCI, provides a step-by-step procedural approach, and discusses the potential benefits of integrating these...
Overcoming challenging anatomy in calcified lesion PCI
22 May 2026 – From EuroPCR 2026
This session focuses on overcoming the challenges posed by complex anatomical variations in calcified lesion PCI. Experts present advanced techniques and hybrid solutions for difficult bifurcation angles, aorto-ostial lesions, and other complex scenarios, emphasizing both innovative and simplified approaches to achieve procedural success.
DCB: what we know and what we do not know
22 May 2026 – From EuroPCR 2026
This session provides a detailed update on drug-coated balloons (DCB) in interventional cardiology, covering the latest clinical data and trials. It identifies scenarios where DCB use is most effective and offers guidance on optimizing procedural techniques to enhance clinical outcomes.
New insights into pharmacological treatment for STEMI
21 May 2026 – From EuroPCR 2026
This session presents the latest pharmacological advances in the treatment of ST-segment elevation myocardial infarction (STEMI). It covers safety data on ticagrelor monotherapy post-primary PCI, the impact of P2Y12 inhibitor pretreatment, effects of dapagliflozin on myocardial remodeling, and considerations for bleeding risk and vascular preparation strategies...
New evidence for coronary revascularisation
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary revascularisation, including the role of CT-derived virtual stenting for procedural optimization, left ventricular unloading during complex PCI, long-term outcomes of FFR-guided PCI versus medical therapy, Impella CP support in high-risk PCI, and comparative results of PCI versus CABG in...
Spontaneous coronary artery dissection management with intracoronary imaging
22 May 2026 – From EuroPCR 2026
Explore the nuanced management of spontaneous coronary artery dissection (SCAD) with a focus on intracoronary imaging. This session examines diagnostic challenges, the limited role of coronary CT angiography, and strategies for managing occlusive SCAD cases, highlighting the evolving understanding of this complex condition.
TAVI in bicuspid - Planning to performance
22 May 2026 – From EuroPCR 2026
Dedicated to transcatheter aortic valve implantation (TAVI) in bicuspid aortic valves, this session examines anatomical assessment, sizing methods, and clinical outcomes. It includes meta-analyses and registry insights, addressing challenges such as stent deformation and leaflet modification to guide optimal TAVI performance in this distinct patient population.
Left main complications - Part 3
21 May 2026 – From EuroPCR 2026
This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.
Multivessel disease or left main disease
22 May 2026 – From EuroPCR 2026
This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.